903-909
Review
Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care
Vincent Launay-Vacher, Jean-Baptiste Rey, Corinne Isnard-Bagnis, Gilbert Deray and Mikael Daouphars
911-921
Original Article
Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand
Henriette Gourdeau, James B. McAlpine, Maxime Ranger, Bryan Simard and Francois Berger, et al.
923-932
Original Article
IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells
Jon Patterson, Vito J. Palombella, Christian Fritz and Emmanuel Normant
933-941
Original Article
Augmented antioxidant status in Tamoxifen treated postmenopausal women with breast cancer on co-administration with Coenzyme Q10, Niacin and Riboflavin
Srinivasan Yuvaraj, Vummidi Giridhar Premkumar, Kothandaraman Vijayasarathy, Sitthu Govindaswamy Dinakaran Gangadaran and Panchanatham Sachdanandam
943-952
Original Article
Suppression of
Bcl-xL
expression by a novel tumor-specific RNA interference system inhibits proliferation and enhances radiosensitivity in prostatic carcinoma cells
Rui Wang, Fang Lin, Xi Wang, Ping Gao and Ke Dong, et al.
953-963
Original Article
A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity
Fanying Meng, Xiaohong Cai, Jianxin Duan, Mark G. Matteucci and Charles P. Hart
965-971
Original Article
Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression
Andrea Rocca, Giuseppe Viale, Richard D. Gelber, Luca Bottiglieri and Shari Gelber, et al.
973-978
Original Article
New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin
Hirokazu Kawano, Shintaro Komaba, Tsugiko Yamasaki, Mitsuyo Maeda and Yoshimitsu Kimura, et al.
979-987
Original Article
Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells
Jianli Chen, Mahesha Adikari, Rajash Pallai, Hemant K. Parekh and Henry Simpkins
989-995
Original Article
Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group
Norikazu Masuda, Tetsuya Taguchi, Takahiro Nakayama, Eiichi Shiba and Masahiro Watatani, et al.
997-1005
Original Article
The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors
Jianjun Lu, John K. Jackson, Martin E. Gleave and Helen M. Burt
1007-1018
Original Article
Different concentrations of berberine result in distinct cellular localization patterns and cell cycle effects in a melanoma cell line
Teresa L. Serafim, Paulo J. Oliveira, Vilma A. Sardao, Ed Perkins and Donna Parke, et al.
1019-1026
Original Article
A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma
E. Gabriela Chiorean, Tomislav Dragovich, John Hamm, Virginia K. Langmuir and Stewart Kroll, et al.
1027-1035
Original Article
Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 μl) blood samples
Erwin R. Boghaert, Kiran M. Khandke, Latha Sridharan, Maureen Dougher and John F. DiJoseph, et al.
1037-1044
Original Article
Plasma and cerebrospinal fluid pharmacokinetics of the novel tetrahydroisoquinoline EDL-155 in rats
Pengfei Song, Fei Ma, Fan Wang, XiangDi Wang and Renukadevi Patil, et al.
1045-1058
Original Article
Disruption of Golgi processing by 2-phenyl benzimidazole analogs blocks cell proliferation and slows tumor growth
Shirley Cruz Lio, Jessica Johnson, Arka Chatterjee, Jeffrey W. Ludwig and Diane Millis, et al.
1059-1067
Clinical Trial Report
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study
Michael D. Prados, W. K. A. Yung, Patrick Y. Wen, Larry Junck and Timothy Cloughesy, et al.
1069-1073
Clinical Trial Report
A phase I clinical trial of low-dose interferon-α-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma
Robert J. Amato and Muhammad Khan
1075-1081
Short Communication
Open AccessCisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor
F. J. P. Hoebers, D. Pluim, A. A. M. Hart, M. Verheij and A. J. M. Balm, et al.
1083-1084
Letter to the Editor
Dermatitis after suspected imatinib–levothyroxine interaction in a patient with gastrointestinal stromal tumor
Evangelos Cholongitas, Chrysoula Pipili, Konstadinos Katsogridakis, Konstadinos Relos and Maria Dasenaki